Condition: Limbal Stem Cell Deficiency · Sponsor: CHU de Quebec-Universite Laval
The study " Autologous cultured corneal epithelium (CECA) for the treatment of corneal lesions associated with limbal stem cell deficiency" is the first clinical trial of this product manufactured at the LOEX laboratory. The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency. The study is a phase I/phase II study with the goal to evaluate safety and efficacy of the CECA graft for the treatment of human patients suffering from limbal stem cell deficiency. The trial is open to all genders. The inclusion of 5 minors is planned.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University Health Network - Toronto Western Hospital | Toronto, Ontario, Canada | Recruiting |
| CIUSSS de l'Est de l'île de Montréal | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre; Centre de Médecine Innovatrice/Centre for Innovative Medicine | Montreal, Quebec, Canada | Recruiting |
| Centre universitaire d'Ophtalmologie CHU de Québec - HSS | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01756365